Hiroyuki Nagashima

Hiroyuki Nagashima

Auto-generated profile, based on publicly available information

Hiroyuki Nagashima

Molecular Immunology and Inflammation Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, USA

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 July 2023 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
YGYuanyuan Gao
Yuanyuan Gao
YWYan Wang
Yan Wang
DCDaniel Chauss
Daniel Chauss
AVAlejandro V. Villarino
Alejandro V. Villarino
VLVerena M. Link
Verena M. Link
VLVanja Lazarevic
Vanja Lazarevic

20 January 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
MFMichael Fedkenheuer
Michael Fedkenheuer
YSYafang Shang
Yafang Shang
SJSeolkyoung Jung
Seolkyoung Jung
KFKevin Fedkenheuer
Kevin Fedkenheuer
SPSolji Park
Solji Park
RCRafael Casellas
Rafael Casellas
Cells undergo tens of thousands of DNA-damaging events each day. Defects in repairing double-stranded breaks (DSBs) can lead to genomic instability, contributing to cancer, genetic disorders, immunological diseases, and developmental defects. Cohesin, a multi-subunit protein complex, plays a crucial role in both chromosome organization and DNA repair by creating architectural loops through chromatin extrusion. However, the mechanisms by which cohesin regulates these distinct processes are not fully understood. In this study, we identify two separate roles for cohesin in DNA repair within mammalian cells. First, cohesin serves as an intrinsic architectural factor that normally prevents interactions between damaged chromatin. Second, cohesin has an architecture-independent role triggered by ATM phosphorylation of SMC1, which enhances the efficiency of repair. Our findings suggest that these two functions work together to reduce the occurrence of translocations and deletions associated with non-homologous end joining, thereby maintaining genomic stability.

20 November 2024 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
HNHiroyuki Nagashima
Hiroyuki Nagashima
JSJustin Shayne
Justin Shayne
KJKan Jiang
Kan Jiang
FPFranziska Petermann
Franziska Petermann
APAleksandra Pękowska
Aleksandra Pękowska
JOJohn J. O’sHea
John J. O’sHea

3 October 2023 in Japanese Journal of Clinical Oncology
Verified
Journal Article
Open access
PDF file
TKTomohiro Kubo
Tomohiro Kubo
JMJoji Muramatsu
Joji Muramatsu
YAYohei Arihara
Yohei Arihara
AMAyako Murota
Ayako Murota
KIKazuma Ishikawa
Kazuma Ishikawa
KTKohichi Takada
Kohichi Takada
Accumulating evidence has demonstrated platinum-based chemotherapy followed by maintenance therapy with a poly Adenosine diphosphate (ADP)-ribose polymerase inhibitor (olaparib) show benefits in unresectable pancreatic cancer with a germline (g)BRCA1/2 mutation. Evaluation of the germline BRCA1 and BRCA2 mutation is essential for making decisions on a treatment strategy for patients with unresectable pancreatic cancer. However, the detection rates of germline BRCA1 and BRCA2 mutations and efficacy of maintenance with olaparib remain undetermined, prospectively, in Japan. In this prospective analysis, the rate of germline BRCA1 and BRCA2 mutations and efficacy of chemotherapy were analyzed in 136 patients with pancreatic cancer who underwent BRACAnalysis® (85 patients) or FoundationOne® CDx (51 patients) between January 2020 and July 2022. A total of six patients (4.4%) had a germline BRCA1 and BRCA2 mutation. Five patients were treated with modified FOLFIRINOX and one with fluorouracil and oxaliplatin. All patients continued platinum-based chemotherapy for ˃4 months and were subsequently treated with olaparib as a maintenance therapy. The response rate to platinum-based chemotherapy in the germline BRCA1 and BRCA2 mutation-positive group was significantly better than that of the germline BRCA1 and BRCA2 mutation-negative group (66% vs 23%, P = 0.04). All patients harbouring a germline BRCA1 and BRCA2 mutation were able to switch to olaparib. The median progression-free survival using olaparib was 5.7 months (range 3.0–9.2). The rate of germline BRCA1 and BRCA2 mutations found in patients with unresectable pancreatic cancer was comparable to those of previous studies. An analysis of germline BRCA1 and BRCA2 mutations has benefits for all patients with unresectable pancreatic cancer with regard to decisions on therapeutic strategies in a clinical practice setting.

6 December 2024 in Science Advances
Verified
Journal Article
Open access
AKAkihisa Kawajiri
Akihisa Kawajiri
JLJing Li
Jing Li
KKKeita Koinuma
Keita Koinuma
ZYZiying Yang
Ziying Yang
HYHye Jin Yoon
Hye Jin Yoon
TKTakeshi Kawabe
Takeshi Kawabe
Memory-phenotype (MP) CD4 + T lymphocytes develop from naïve cells via self-recognition at homeostasis. While previous studies defined MP cells as a heterogeneous population that comprises T helper 1 (T H 1)/17–like subsets, functional significance of the T-bet − Rorγt − subpopulation remains unknown. Here we show that MP lymphocytes as a whole population can differentiate into T H 1/17/regulatory T (T reg ) cells to mediate mild and persistent inflammation in lymphopenic environments, whereas naïve cells exhibit strong, T H 1-dominated responses. Moreover, we demonstrate that MP lymphocytes comprise not only T H 1/17-differentiated subsets but a polyclonal, transcriptomically immature “undifferentiated” subpopulation at homeostasis. Furthermore, our data argue that while the T-bet + Rorγt − MP subset is terminally T H 1-differentiated, its undifferentiated counterpart retains the capacity to rapidly proliferate to differentiate into T H 1/17/T reg cells, with the latter response tonically constrained by preexisting T reg cells. Together, our results identify undifferentiated MP CD4 + T lymphocytes as a unique precursor that has a diverse differentiation potential to generate T H 1/17/T reg cells to contribute to pathogenesis of inflammation.

1 July 1996 in Chemical Physics Letters
Verified
Journal Article
Closed access
MYMinoru Yoshimoto
Minoru Yoshimoto
TYTomohiko Yamaguchi
Tomohiko Yamaguchi
HNHiroyuki Nagashima
Hiroyuki Nagashima